David B. Karpf - 01 Feb 2023 Form 4 Insider Report for LUMOS PHARMA, INC.

Reporting relationship: Chief Medical Officer
Issuer ticker: N/A
Reported as of: 01 Feb 2023
Net transaction value: +$3,393
SEC form: 4
Accepted by SEC: 03 Feb 2023, 16:02:52 UTC
Prior SEC filing: 06 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Ryan Trytten, attorney-in-fact

Key filing fact

David B. Karpf filed Form 4 for LUMOS PHARMA, INC. on 03 Feb 2023.

Key facts

This page summarizes David B. Karpf's Form 4 filing for LUMOS PHARMA, INC..
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2023, 16:02.

Change

Previous filing in this sequence was filed on 06 Sep 2022.
Current net transaction value: +$3,393.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LUMO transaction

Common Stock

Award

Transaction value: $3,520
Shares: +1,000
Change %: +14%
Price: $3.52
Shares after: 8,330
Date: 01 Feb 2023
Ownership: Direct
Footnotes: F1, F2, F3

LUMO transaction

Common Stock

Tax liability

Transaction value: $127
Shares: -36
Change %: -0.43%
Price: $3.52
Shares after: 8,294
Date: 01 Feb 2023
Ownership: Direct
Footnotes: F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LUMO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +12,000
Change %
Price: $0.000000
Shares after: 12,000
Date: 01 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,000
Exercise price: $3.52
Footnotes: F5, F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Represents shares issued as restricted stock units ("RSUs") under the Issuer's 2009 Equity Incentive Plan, as amended, (the "Plan") that were received as an award, for no consideration. The RSUs vest in a series of four successive annual installments beginning on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

Footnote F2

Includes 300 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

Footnote F3

Includes 5,625 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on September 1, 2023, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.

Footnote F4

Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 100 previously reported RSUs granted to the Reporting Person.

Footnote F5

Grant to the Reporting Person of a stock option under the Plan. 50% of the option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on March 1, 2023, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the Date of Grant.

Footnote F6

The remaining 50% of the stock options vest and become exercisable in 3 substantially equal tranches on the first of the month following an increase of closing stock price, as defined as the closing stock price on Nasdaq Stock Market by at least 50%, 100% and 150%, respectively, above the closing stock on December 31, 2022, when measured over 30 consecutive calendar days, provided such increase occurs within two years of the Date of Grant, otherwise such options shall be cancelled.

Footnote F7

Unless otherwise disclosed, the option expires ten years after the date of grant.